
Patients with a certain form of aggressive prostate cancer could benefit from a new combination of drugs which slow cancer growth, according to a new study.
Academics said their findings support wider use of genetic testing for cancer patients after their study showed that patients with certain genetic mutations appeared to benefit more than others.